Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Share:
Related
Here Are All The Big Biotech Mergers In 2016
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
August S&P500 Aristocrats Achieve Overbought Bloat (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2016BMO CapitalDowngradesOutperformMarket Perform
Jun 2016Morgan StanleyDowngradesOverweightEqual-weight
Jun 2016Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!